Bank of New York Mellon Corp Has $2.99 Million Holdings in Sangamo Therapeutics, Inc. (SGMO)

Bank of New York Mellon Corp raised its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 2.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 339,842 shares of the biopharmaceutical company’s stock after purchasing an additional 6,537 shares during the period. Bank of New York Mellon Corp owned 0.47% of Sangamo Therapeutics worth $2,990,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Aperio Group LLC bought a new position in Sangamo Therapeutics in the 2nd quarter valued at $108,000. Fox Run Management L.L.C. bought a new position in Sangamo Therapeutics in the 2nd quarter valued at $126,000. Russell Investments Group Ltd. bought a new position in Sangamo Therapeutics in the 2nd quarter valued at $203,000. Bank of America Corp DE boosted its holdings in Sangamo Therapeutics by 49.9% in the 1st quarter. Bank of America Corp DE now owns 32,625 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 10,861 shares during the period. Finally, HighTower Advisors LLC boosted its holdings in Sangamo Therapeutics by 0.3% in the 1st quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 100 shares during the period. 63.43% of the stock is owned by hedge funds and other institutional investors.

In related news, Director William R. Ringo sold 31,000 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $14.37, for a total transaction of $445,470.00. Following the completion of the transaction, the director now owns 31,800 shares in the company, valued at $456,966. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the transaction, the vice president now owns 35,517 shares of the company’s stock, valued at approximately $355,170. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 87,474 shares of company stock valued at $1,169,009. 5.50% of the stock is owned by company insiders.

Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) opened at 15.90 on Wednesday. The stock’s 50 day moving average is $13.82 and its 200-day moving average is $8.97. The company’s market capitalization is $1.33 billion. Sangamo Therapeutics, Inc. has a 12-month low of $2.65 and a 12-month high of $17.06.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The firm had revenue of $8.30 million during the quarter, compared to analyst estimates of $5.82 million. During the same quarter in the prior year, the business earned ($0.38) earnings per share. Sangamo Therapeutics’s revenue for the quarter was up 124.3% on a year-over-year basis. Analysts anticipate that Sangamo Therapeutics, Inc. will post ($0.82) earnings per share for the current year.

Several brokerages have commented on SGMO. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a report on Thursday, September 14th. Wells Fargo & Company reissued an “outperform” rating and issued a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Friday, August 18th. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Piper Jaffray Companies set a $8.00 price objective on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $14.40.

ILLEGAL ACTIVITY WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/10/11/bank-of-new-york-mellon-corp-has-2-99-million-holdings-in-sangamo-therapeutics-inc-sgmo.html.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply